医脉通编辑整理,未经授权请勿转载。
日本血液学会(JSH)第87届年会将于2025年10月10日至12日在日本神户盛大召开。会议始终以“打造富有成效的行业交流平台”为目标,从议程设计到服务保障层层细化,力求为全球血液学领域从业者呈现一场兼具深度与温度的专业会议。
本届年会以“延续与连通”为核心主题,既是对血液学领域过往学术成果的致敬与传承,更旨在打破地域、学科边界,深化全球同行间的交流合作。在以往学术互动的基础上,我们期待通过本届会议搭建更广阔的对话桥梁——让前沿研究成果在这里碰撞、临床实践经验在这里共享、跨领域合作契机在这里诞生,将每一次思想互动转化为推动血液学发展的力量,为领域进步注入新动能。本届年会ORAL部分入选专家名单正式出炉,快来一睹专家阵容!
摘要号 | 英文标题 | 报告人及单位 |
O1-13A-1 | Safety and efficacy of bicistronic CD19/CD22 CAR T cell therapy in treatment of childhood R/R B-ALL | Hua Zhang,上药生物治疗(香港)有限公司 |
O1-15A-5 | Hepatitis C virus and prognosis of hematologic malignancies: a propensity score matching analysis | Wan-Shiuan Lin,台湾康宁大学 |
O1-15A-6 | Respiratory syncytial virus: a significant cause of respiratory failure in hematologic malignancies | ZongHan Yao,国立台湾大学医学院附设医院 |
O1-17D-5 | The prognostic value of circulating cell-free methylated EBV-DNA in extranodal NK/T cell lymphoma | Tong-Yao Xing,南京医科大学第一附属医院(江苏省人民医院) |
O1-17D-6 | ABBV-CLS-484 disrupts mitochondrial renewal and mitophagy to exert anti-tumor activities in ALK+ALCL | 梁金花,南京医科大学第一附属医院(江苏省人民医院) |
O1-18C-2 | Glofitamab plus selinexor as salvage therapy for relapsed primary central nervous system lymphoma | Qu Cui,首都医科大学 |
O1-18C-4 | Preliminary exploration of R-MIAD in the treatment of newly diagnosed PCNSL | Yuedan Chen,首都医科大学 |
O1-19A-3 | Exome and transcriptome sequencing reveal prognostic mutation genes in Chinese MM | Ling Zhong,四川省人民医院 |
O2-3A-3 | BRD4 inhibition by MS-417 suppresses TAL1 expression and proliferation in T-ALL cells | 赵维莅,上海交通大学医学院附属瑞金医院 |
O2-3A-4 | The anti-leukemic effect of a new CX4945 biomimetic nanodrug in B-cell acute lymphoblastic leukemia | Yan Wang,东南大学附属中大医院 |
O2-3B-1 | Relapse risk and outcome of discontinuing asparaginase in children with acute lymphoblastic leukemia | Xingchen Wang,中国医学科学院血液病医院(中国医学科学院血液学研究所) |
O2-3B-3 | Synergy efficacy of HDACi and CX-4945 by targeting TCL1A in B-cell acute lymphoblastic leukemia | Huimin Xiang,东南大学附属中大医院 |
O2-3B-6 | Azathioprine in childhood acute lymphoblastic leukemia: a single-center retrospective study | Jianhua Feng,宁波大学附属妇女儿童医院 |
O2-4C-1 | Single-cell analysis reveals myeloid bias and therapeutic targets in pediatric NRAS-mutant neoplasms | Su Y. Zong,中国医学科学院血液病医院(中国医学科学院血液学研究所) |
O2-5A-1 | Efficacy and safety of HSK39297 monotherapy in patients with paroxysmal nocturnal hemoglobinuria | Yuemin Gong,南京医科大学第一附属医院(江苏省人民医院) |
O2-5A-4 | Iptacopan combined with immunosuppressants for refractory AIHA: a report of three cases | 许书倩,山东大学齐鲁医院 |
O2-9A-3 | Long-term remission with CD19/22 CART or in combination with ASCT in TP53-altered B-NHL | Juan Peng,华中科技大学同济医学院附属同济医院 |
O2-9B-1 | Prognostic role of SOCS1 mutations in diffuse large B-cell lymphoma | Xinyi Zhang,南京医科大学第一附属医院(江苏省人民医院) |
O2-9B-2 | Molecular features encoded in dynamic ctDNA monitoring reveal prognosis and clone evolution in DLBCL | 梁金花,南京医科大学第一附属医院(江苏省人民医院) |
O2-9B-3 | A novel CD58 mutation-related signature predicts prognosis risk in diffuse large B-cell lymphoma | ChunYu Shang,南京医科大学第一附属医院(江苏省人民医院) |
O2-9B-4 | Identifying the truly low-risk patients with TNFRSF14 mutation in diffuse large B cell lymphoma | Wei Hua,南京医科大学第一附属医院(江苏省人民医院) |
O2-11C-6 | NSUN2-mediated m5C modification regulates PHGDH and immune evasion in high-grade B-cell lymphoma | Guojun Zhang,中国医科大学附属盛京医院 |
O2-15D-1 | Comparasion of hetrombopag versus eltrombopag combined with ATG/CyA as first-line therapy for SAA | Jingnan Sun,吉林大学第一医院 |
O2-15D-2 | Association of cyclosporin concentration with related adverse events in patients of aplastic anemia | Lingxiao Xing,中国医学科学院血液病医院(中国医学科学院血液学研究所) |
O2-15D-3 | Management strategy in AA patients with HBV infection following intensive immunosuppressive therapy | Yawen Zhang,南京医科大学第一附属医院(江苏省人民医院) |
O2-16C-2 | Innovative synergy of flavonoid GL-V9 and EZH2 inhibitor in AML: in vitro and in vivo insights | Chan Yang,东南大学附属中大医院 |
O2-16D-2 | ACTR5 mutation as a prognostic factor in acute myeloid leukemia receiving 3+7 therapy | Jinping He,广州医科大学 |
O2-17D-3 | Sorafenib reverses venetoclax resistance in AML via downregulation of the Ras-Raf-MEK-ERK pathway | Yutong Jin,安徽中医药大学 |
O2-17D-6 | Small-molecule RPB1 degraders eradicate acute myeloid leukemia | Shu wen Zheng,浙江大学医学院附属第二医院 |
O2-18A-3 | Immune landscape profiling in patients with advanced myeloid malignancies receiving azacitidine | Feng-Ming Tien,国立台湾大学医学院附设医院 |
O2-18C-3 | Clinical efficacy and safety of VAH and VAHA regimen in newly diagnosed AML patients | Xin Yan,东南大学附属中大医院 |
O2-18D-5 | The prognostic significance of PWWP2B expression in AML patients treated with intensive chemotherapy | Cheng Yeh Chen,国立台湾大学医学院附设医院 |
O3-4C-4 | Comparative analysis of secondary malignancies in MF patients treated with ruxolitinib | Yu-Guanscg Chen,台湾三军总医院 |
O3-4C-5 | Clinical features, gene alterations, and outcomes in primary myelofibrosis with ring sideroblasts | Junyun Liu,中国医学科学院血液病医院(中国医学科学院血液学研究所) |
O3-8B-1 | Clinical implication of residual genetic mutations at CR in acute myeloid leukemia | Xin Yan,东南大学附属中大医院 |
O3-8B-2 | Prognostic implications of BCMA, BAFF, and APRIL expression in patients with acute myeloid leukemia | Yun-Tzu Lin,国立台湾大学医学院附设医院 |
O3-8B-3 | A clinically actionable prognostic model for infant acute myeloid leukemia | Yu Tao,重庆医科大学附属儿童医院 |
O3-8B-4 | Identification of a stress-adapted pDC-like leukemic stem cell program in pDC-AML by multi-omics | Xingcheng Yang,华中科技大学同济医学院附属同济医院 |
O3-14A-2 | Risk factors, and imaging findings of bronchiolitis obliterans syndrome after allogeneic SCT | Ting-Yu Liao,国立台湾大学医学院附设医院 |
O3-14A-5 | Prognostic value of patient telomere length in Allo-HSCT for hematologic malignancies | Hengwei Wu,宁波市鄞州人民医院 |
O3-14B-2 | Machine learning-based prediction of stem cell harvest success: a single institution experience | Heng Lee,台北荣民总医院 |
O3-17D-2 | DNA methylation variability in pediatric aplastic anemia contributes to T cell differentiation | Inan Wang,上海交通大学医学院附属上海儿童医学中心 |
O3-18A-6 | Bortezomib in VRCAP/VRDHAP induction improves outcomes in untreated mantle cell lymphoma | Wan-Chen Hsieh,国立台湾大学医学院附设医院 |
排名不分先后,按照摘要号进行排序
如有遗漏或任何问题,请给我们留言~
本文仅筛选了报告人来自中国的研究
(本网站所有内容,凡注明来源为“医脉通”,版权均归医脉通所有,未经授权,任何媒体、网站或个人不得转载,否则将追究法律责任,授权转载时须注明“来源:医脉通”。本网注明来源为其他媒体的内容为转载,转载仅作观点分享,版权归原作者所有,如有侵犯版权,请及时联系我们。)